TY  - JOUR
T1  - ADding behavioral therapy to medication for smoking cessation
AU  - Goldman J, Shytle R, Sanberg PR
Y1  - 1999/06/02
N1  - 10-1001/pubs.JAMA-ISSN-0098-7484-281-21-jbk0602
JO  - JAMA
SP  - 1983
EP  - 1985
VL  - 281
IS  - 21
N2  - 
Rose and colleagues2 have demonstrated the therapeutic
utility of combining the nicotine antagonist mecamylamine with nicotine
for the treatment of smoking cessation. These investigators
demonstrated that mecamylamine given orally with nicotine patches
significantly prolonged the duration of continuous smoking
abstinence.2 Furthermore, this combination reduced ad-lib
smoking, smoking satisfaction, and cigarette craving. These studies
have promoted the development of the mecamylamine nicotine patch
currently in phase 3 clinical trials. However, it is now possible to
use oral mecamylamine and nicotine patches as was done in the study by
Rose et al.

SN  - 0098-7484
M3  - doi: 10-1001/pubs.JAMA-ISSN-0098-7484-281-21-jbk0602
UR  - http://dx.doi.org/10-1001/pubs.JAMA-ISSN-0098-7484-281-21-jbk0602
ER  -